DGX Quest Diagnostics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
08:30
Jul 23
Jul 23
Management raised full-year guidance for the second time, citing strong organic growth driven by broad clinical demand, automation gains, and robust performance across channels.
HIGH
13:46
May 28
May 28
Vitalik Buterin expresses disappointment in the DGX spark project.
Vitalik Buterin expresses disappointment in the DGX spark project, reflecting negative sentiment but without a forward-looking trade call.
LOW
13:00
Apr 30
Apr 30
Management expects the pipeline of hospital and regional lab deals to strengthen if PAMA goes into effect in January, as smaller labs will struggle to compete with scale players like LabCorp. — PAMA implementation could accelerate consolidation in the lab industry, benefiting large-scale players like LabCorp and Quest Diagnostics.
MED
08:30
Apr 21
Apr 21
Management raised full-year revenue and EPS guidance after a strong Q1 driven by broad-based organic growth, advanced diagnostics, and productivity improvements from automation and AI.
HIGH
08:30
Feb 10
Feb 10
Management issued guidance for 6-7% revenue growth and expanding margins, backed by strong organic volume, advanced diagnostics momentum, and consumer channel growth, despite weather headwinds.
HIGH
08:30
Oct 21
Oct 21
Quest raised full-year guidance on broad-based demand, organic growth acceleration, and margin expansion, signaling sustained momentum.
HIGH
About DGX Analyst Coverage
Buzzberg tracks DGX (Quest Diagnostics) across 2 sources. 0 bullish vs 0 bearish calls from 4 analysts. Sentiment: evenly split. 6 total trade ideas tracked. Latest voices: Sam Samad, Vitalik Buterin, Adam Schechter.